





UNDERSTANDING THE RISK OF BAT CORONAVIRUS EMERGENCE

Award Number: R01AI10956
ORGANISATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPORD: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY: ☒ Issue Date FY ☐ Funding FY

VIEW AWARD ABSTRACT

Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTRY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount
* Issue Date FY: 2021 (Subtotal = \$0)														
2021	2019	ECONHEALTH ALLIANCE INC.	520 BTH AV...	NEW YORK	NY	10018	NEW YORK	USA	Allergy and Infectious Diseases Research	000	6	9/14/2021	COMPETING CONTINUATION	\$0
* Issue Date FY: 2020 (Subtotal = \$0)														
2020	2019	ECONHEALTH ALLIANCE INC.	460 W 34T...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	6	4/27/2020	COMPETING CONTINUATION	\$369,819
2020	2019	ECONHEALTH ALLIANCE INC.	460 W 34T...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	001	6	7/13/2020	COMPETING CONTINUATION	\$369,819
* Issue Date FY: 2019 (Subtotal = \$661,980)														
2019	2019	ECONHEALTH ALLIANCE INC.	460 W 34T...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	6	7/24/2019	COMPETING CONTINUATION	\$733,750
2019	2019	ECONHEALTH ALLIANCE INC.	460 W 34T...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	001	6	8/5/2019	COMPETING CONTINUATION	\$71,770
* Issue Date FY: 2018 (Subtotal = \$581,646)														
2018	2018	ECONHEALTH ALLIANCE INC.	460 W 34T...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	5	6/18/2018	NON-COMPETING CONTINUATION	\$581,646
* Issue Date FY: 2017 (Subtotal = \$597,112)														
2017	2017	ECONHEALTH ALLIANCE INC.	460 W 34T...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	4	5/26/2017	NON-COMPETING CONTINUATION	\$597,112
* Issue Date FY: 2016 (Subtotal = \$611,000)														
2016	2016	ECONHEALTH ALLIANCE INC.	1200 LINCOLN...	PROSPECT ...	PA	19076	DELAWARE	USA	Allergy and Infectious Diseases Research	000	3	7/22/2016	NON-COMPETING CONTINUATION	\$611,000
* Issue Date FY: 2015 (Subtotal = \$630,445)														
2015	2015	ECONHEALTH ALLIANCE INC.	1200 LINCOLN...	PROSPECT ...	PA	19076	DELAWARE	USA	Allergy and Infectious Diseases Research	000	2	6/10/2015	NON-COMPETING CONTINUATION	\$630,445
* Issue Date FY: 2014 (Subtotal = \$666,442)														
2014	2014	ECONHEALTH ALLIANCE INC.	1200 LINCOLN...	PROSPECT ...	PA	19076	DELAWARE	USA	Allergy and Infectious Diseases Research	000	1	5/27/2014	NEW	\$666,442
														Grand Total All Awards = \$3,748,755

But ukraine biolabs smh.. don't worry I'll drop the source at the end of the thread this needs to be addressed seriously

UNDERSTANDING THE RISK OF BAT CORONAVIRUS EMERGENCE

Award Number: R01AI110964
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIAID
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY: ☒ Issue Date FY ☐ Funding FY

VIEW AWARD ABSTRACT

Project Summary: Understanding the Risk of Bat Coronavirus Emergence Novel zoonotic, bat-origin CoVs are a significant threat to global health and food security, as the cause of SARS in China in 2002, the ongoing outbreak of MERS, and of a newly emerged Swine Acute Diarrhea Syndrome in China. In a previous R01 we found that bats in southern China harbor an extraordinary diversity of SARS-CoV, some of which can use human ACE2 to enter cells, infect humanized mouse models causing SARS-like illness, and evade available therapies or vaccines. We found that people living close to bat habitats are the primary risk groups for spillover, that at one site diverse SARS-CoV exist that contain every genetic element of the SARS-CoV genome, and identified serological evidence of human exposure among people living nearby. These findings have led to 18 published peer-reviewed papers, including two papers in Nature, and a review in Cell. Yet salient questions remain on the origin, diversity, capacity to cause illness, and risk of spillover of these viruses. In this R01 renewal we will address these issues through 3 specific aims: Aim 1. Characterize the diversity and distribution of high spillover-risk SARS-CoV in bats in southern China. We will use phylogeographic and viral discovery curve analyses to target additional bat sample collection and molecular CoV screening to fill in gaps in our previous sampling and fully characterize natural SARS-CoV diversity in southern China. We will sequence receptor binding domains (spike protein) to identify viruses with the highest potential for spillover which we will include in our experimental investigations (Aim 3). Aim 2. Community- and clinic-based syndromic surveillance to capture SARS-CoV spillover, routes of exposure and potential public health consequences. We will conduct biological-behavioral surveillance in high-risk populations, with known bat contact, in community and clinical settings to 1) identify risk factors for serological and PCR evidence of bat SARS-CoV; 2) assess possible health effects of SARS-CoV infection in people. We will analyze bat-CoV serology against human wildlife contact and exposure data to quantify risk factors and health impacts of SARS-CoV spillover. Aim 3. In vitro and in vivo characterization of SARS-CoV spillover risk, coupled with spatial and phylogenetic analyses to identify the regions and viruses of public health concern. We will use S protein sequence data, infectious clone technology, in vitro and in vivo infection experiments and analysis of receptor binding to test the hypothesis that % divergence thresholds in S protein sequences predict spillover potential. We will combine these data with bat host distribution, viral diversity and phylogeny, human survey of risk behaviors and illness, and serology to identify SARS-CoV spillover risk hotspots across southern China. Together these data and analyses will be critical for the future development of public health interventions and enhanced surveillance to prevent the re-emergence of SARS or the emergence of a novel SARS-CoV.

Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTRY	Legal Entity COUNTRY	Audience Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount
+ Issue Date FY: 2021 (Subtotal = \$0)														
2021	2019	ECOEALTH ALLIANCE INC.	520 8TH AV...	NEW YORK	NY	10018	NEW YORK	USA	Allergy and Infectious Diseases Research	000	6	9/16/2021	COMPETING CONTINUATION	\$0
+ Issue Date FY: 2020 (Subtotal = \$0)														
2020	2019	ECOEALTH ALLIANCE INC.	460 W 34TH...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	6	4/27/2020	COMPETING CONTINUATION	\$368,819
2020	2019	ECOEALTH ALLIANCE INC.	460 W 34TH...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	001	6	7/13/2020	COMPETING CONTINUATION	\$368,819
+ Issue Date FY: 2019 (Subtotal = \$661,982)														
2019	2019	ECOEALTH ALLIANCE INC.	460 W 34TH...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	6	7/24/2019	COMPETING CONTINUATION	\$733,770
2019	2019	ECOEALTH ALLIANCE INC.	460 W 34TH...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	001	6	8/5/2019	COMPETING CONTINUATION	\$671,770
+ Issue Date FY: 2018 (Subtotal = \$581,646)														
2018	2018	ECOEALTH ALLIANCE INC.	460 W 34TH...	NEW YORK	NY	10001	NEW YORK	USA	Allergy and Infectious Diseases Research	000	5	6/18/2018	NON-COMPETING CONTINUATION	\$581,646

<https://t.co/6P3Tu15YIS>

Award Information



UNDERSTANDING THE RISK OF BAT CORONAVIRUS EMERGENCE

Award Number: R01AI110964**ORGANIZATION:** NATIONAL INSTITUTE OF
ALLERGY & INFECTIOUS DISEASES**OPDIV:** NIH**AWARD CLASS:** DISCRETIONARY**AWARD ACTIVITY TYPE:**
SCIENTIFIC/HEALTH RESEARCH
(INCLUDES SURVEYS)

Issue

[VIEW AWARD ABSTRACT](#)

Date

FY

Project Summary: Understanding the Risk of Bat Coronavirus Emergence Novel zoonotic, bat-origin CoVs are a significant threat to global health and food security, as the cause of SARS in China in 2002, the ongoing outbreak of MERS, and of a newly emerged Swine Acute Diarrhea Syndrome in China. In a previous R01 we found that bats in southern China harbor an extraordinary diversity of SARSr-CoVs, some of which can use human ACE2 to enter cells, infect humanized mouse models causing SARS-like illness, and evade available therapies or vaccines. We found that people living close to bat habitats are the primary risk groups for spillover, that at one site diverse SARSr-CoVs exist that contain every genetic element of the SARS-CoV genome, and identified serological evidence of human exposure among people living nearby. These findings have led to 18 published peer-reviewed papers, including two papers in Nature, and a review in Cell. Yet salient questions remain on the origin, diversity, capacity to cause illness, and risk of spillover of these viruses. In this R01 renewal we will address these issues through 3 specific aims: Aim 1. Characterize the diversity and distribution of high spillover-risk SARSr-CoVs in bats in southern China. We will use phylogeographic and viral discovery curve analyses to target additional bat sample collection and molecular CoV screening to fill in gaps in our previous sampling and fully characterize natural SARSr-CoV diversity in southern China. We will sequence receptor binding domains (spike proteins) to identify viruses with the highest potential for spillover which we will include in our experimental investigations (Aim 3). Aim 2. Community, and clinic-based syndromic, surveillance to capture SARSr-CoV spillover, routes of

▼ Issue Date FY: 2021 (Subtotal = \$0)

Issue Date FY: 2021
Funding FY: 2019
Legal Entity Name:
Legal Entity Address: 520 8TH AVE RM 1200
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10018
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing:

Award Code: 000
Budget Year: 6
Action Date: 9/14/2021
Action Type: COMPETING CONTINUATION
Action Amount: \$0

▼ Issue Date FY: 2020 (Subtotal = \$0)

Issue Date FY: 2020
Funding FY: 2019
Legal Entity Name: ECOHEALTH ALLIANCE INC.
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research

Award Code: 000
Budget Year: 6
Action Date: 4/27/2020
Action Type: COMPETING CONTINUATION
Action Amount: -\$369,819

Issue Date FY: 2020
Funding FY: 2019
Legal Entity Name:
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY



Issue Date FY: 2020
Funding FY: 2019
Legal Entity Name:
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing:

Award Code: 001
Budget Year: 6
Action Date: 7/13/2020
Action Type: COMPETING CONTINUATION
Action Amount: \$369,819

▼ Issue Date FY: 2019 (Subtotal = \$661,980)

Issue Date FY: 2019
Funding FY: 2019
Legal Entity Name: ECOHEALTH ALLIANCE INC
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research

Award Code: 000
Budget Year: 6
Action Date: 7/24/2019
Action Type: COMPETING CONTINUATION
Action Amount: \$733,750

Issue Date FY: 2019
Funding FY: 2019
Legal Entity Name:
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK



Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing:

Award Code: 001
Budget Year: 6
Action Date: 8/5/2019
Action Type: COMPETING CONTINUATION
Action Amount: -\$71,770

▼ Issue Date FY: 2018 (Subtotal = \$581,646)

Issue Date FY: 2018
Funding FY: 2018
Legal Entity Name: ECHOHEALTH ALLIANCE INC
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research
Award Code: 000
Budget Year: 5
Action Date: 6/18/2018
Action Type: NON-COMPETING CONTINUATION
Action Amount: \$581,646

▼ Issue Date FY: 2017 (Subtotal = \$597,112)

Issue Date FY: 2017
Funding FY: 2017
Legal Entity Name:
Legal Entity Address: 460 W 34TH ST 17TH FL
Legal Entity City: NEW YORK
Legal Entity State: NY
Legal Entity Zip Code: 10001
Legal Entity COUNTY: NEW YORK
Legal Entity COUNTRY:USA
Assistance Listing:

Award Code: 000



Assistance Listing:

Award Code: 000
Budget Year: 4
Action Date: 5/26/2017
Action Type: NON-COMPETING CONTINUATION
Action Amount: \$597,112

▼ Issue Date FY: 2016 (Subtotal = \$611,090)

Issue Date FY: 2016
Funding FY: 2016
Legal Entity Name: ECOHEALTH ALLIANCE INC
Legal Entity Address: 1200 LINCOLN AVENUE
Legal Entity City: PROSPECT PARK
Legal Entity State: PA
Legal Entity Zip Code: 19076
Legal Entity COUNTY: DELAWARE
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research

Award Code: 000
Budget Year: 3
Action Date: 7/22/2016
Action Type: NON-COMPETING CONTINUATION
Action Amount: \$611,090

▼ Issue Date FY: 2015 (Subtotal = \$630,445)

Issue Date FY: 2015
Funding FY: 2015
Legal Entity Name: ECOHEALTH ALLIANCE INC
Legal Entity Address: 1200 LINCOLN AVENUE
Legal Entity City: PROSPECT PARK
Legal Entity State: PA
Legal Entity Zip Code: 19076
Legal Entity COUNTY: DELAWARE
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research

Award Code: 000
Budget Year: 2
Action Date: 6/10/2015
Action Type: NON-COMPETING CONTINUATION



▼ Issue Date FY: 2015 (Subtotal = \$630,445)

Issue Date FY: 2015
Funding FY: 2015
Legal Entity Name: ECOHEALTH ALLIANCE INC
Legal Entity Address: 1200 LINCOLN AVENUE
Legal Entity City: PROSPECT PARK
Legal Entity State: PA
Legal Entity Zip Code: 19076
Legal Entity COUNTY: DELAWARE
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research
Award Code: 000
Budget Year: 2
Action Date: 6/10/2015
Action Type: NON-COMPETING CONTINUATION
Action Amount: \$630,445

▼ Issue Date FY: 2014 (Subtotal = \$666,442)

Issue Date FY: 2014
Funding FY: 2014
Legal Entity Name: ECOHEALTH ALLIANCE INC
Legal Entity Address: 1200 LINCOLN AVENUE
Legal Entity City: PROSPECT PARK
Legal Entity State: PA
Legal Entity Zip Code: 19076
Legal Entity COUNTY: DELAWARE
Legal Entity COUNTRY:USA
Assistance Listing: Allergy and Infectious Diseases
Research
Award Code: 000
Budget Year: 1
Action Date: 5/27/2014
Action Type: NEW
Action Amount: \$666,442



Sum of Action Amount is \$3,748,715; Grand Total = \$3,748,715

B00M

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY: ☒ Issue Date FY ☐ Funding FY

HIDE AWARD ABSTRACT

Project Summary: Understanding the Risk of Bat Coronavirus Emergence Novel zoonotic, bat-origin CoVs are a significant threat to global health and food security, as the cause of SARS in China in 2002, the ongoing outbreak of MERS, and of a newly emerged Swine Acute Diarrhea Syndrome in China. In a previous R01 we found that bats in southern China harbor an extraordinary diversity of SARSr-CoVs, some of which can use human ACE2 to enter cells, infect humanized mouse models causing SARS-like illness, and evade available therapies or vaccines. We found that people living close to bat habitats are the primary risk groups for spillover, that at one site diverse SARSr-CoVs exist that contain every genetic element of the SARS-CoV genome, and identified serological evidence of human exposure among people living nearby. These findings have led to 18 published peer-reviewed papers, including two papers in Nature, and a review in Cell. Yet salient questions remain on the origin, diversity, capacity to cause illness, and risk of spillover of these viruses. In this R01 renewal we will address these issues through 3 specific aims: Aim 1. Characterize the diversity and distribution of high spillover-risk SARSr-CoVs in bats in southern China. We will use phylogeographic and viral discovery curve analyses to target additional bat sample collection and molecular CoV screening to fill in gaps in our previous sampling and fully characterize natural SARSr-CoV diversity in southern China. We will sequence receptor binding domains (spike proteins) to identify viruses with the highest potential for spillover which we will include in our experimental investigations (Aim 3). Aim 2. Community, and clinic-based syndromic surveillance to capture SARSr-CoV spillover, routes of exposure and potential public health consequences. We will conduct biological-behavioral surveillance in high-risk populations, with known bat contact, in community and clinical settings to 1) identify risk factors for serological and PCR evidence of bat SARSr-CoVs; 2) assess possible health effects of SARSr-CoVs infection in people. We will analyze bat-CoV serology against human-wildlife contact and exposure data to quantify risk factors and health impacts of SARSr-CoV spillover. Aim 3. In vitro and in vivo characterization of SARSr-CoV spillover risk, coupled with spatial and phylogenetic analyses to identify the regions and viruses of public health concern. We will use S protein sequence data, infectious clone technology, in vitro and in vivo infection experiments and analysis of receptor binding to test the hypothesis that % divergence thresholds in 5 protein sequences predict spillover potential. We will combine these data with bat host distribution, viral diversity and phylogeny, human survey of risk behaviors and illness, and serology to identify SARSr-CoV spillover risk hotspots across southern China. Together these data and analyses will be critical for the future development of public health interventions and enhanced surveillance to prevent the re-emergence of SARS or the emergence of a novel SARSr-CoV.